Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.16
-0.14 (-1.51%)
At close: Jun 18, 2026, 4:00 PM EDT
9.11
-0.05 (-0.52%)
After-hours: Jun 18, 2026, 6:45 PM EDT
Vir Biotechnology Employees
Vir Biotechnology had 367 employees as of December 31, 2025. The number of employees decreased by 41 or -10.05% compared to the previous year.
Employees
367
Change (1Y)
-41
Growth (1Y)
-10.05%
Revenue / Employee
$178,460
Profits / Employee
-$1,206,313
Market Cap
1.54B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 367 | -41 | -10.05% |
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Sep 30, 2021 | 395 | 98 | 33.00% |
| Jun 30, 2021 | 367 | 114 | 45.06% |
| Mar 31, 2021 | 340 | 103 | 43.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Ascentage Pharma Group International | 767 |
| Novavax | 749 |
| Immunocore Holdings | 524 |
| UroGen Pharma | 298 |
| Monte Rosa Therapeutics | 187 |
| Septerna | 130 |
| MoonLake Immunotherapeutics | 130 |
VIR News
- 8 days ago - Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley - TheFly
- 9 days ago - Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - Business Wire
- 24 days ago - Vir Biotechnology Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TheFly
- 4 weeks ago - Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire
- 5 weeks ago - Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley - TheFly
- 6 weeks ago - Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year - TheFly